Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-NY108 PET Imaging in Prostatic Cancer
NCT05623878Phase 1Unknown
- Sponsor
- Affiliated Hospital of Jiangnan University
- Start
- Jan 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of 68Ga-NYM032 in prostate cancer (PCa), sponsored by Affiliated Hospital of Jiangnan University. Primary endpoint: Tissue distribution of 68Ga-Anti-PSMA mAbs(NY108) at 1 year. Status: unknown.
02
Drugs
68Ga-NYM032
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05623878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05623878.